How does it work? What benefits does it offer? What risks does its use hide? Is there a legal option with corresponding training benefits?

Obesity and related metabolic disorders, such as hyperlipidemia and non-alcoholic fatty liver disease, have become ...

Amgen is planning to push its olpasiran candidate for reducing lipoprotein(a) into phase 3 as quickly as possible as it tries to catch up with rival programmes at Novartis. The US biotech has just ...

The proposed mechanisms for the effects of POM3 on the lipoprotein lipid profile are depicted in Figure 3 [39] and involve two predominant effects: first, reduced hepatic secretion of TG-rich VLDL ...

Lipoprotein(a) is well established as a risk factor for cardiovascular disease, but patients rarely get tested for it. Now, an alliance between Novartis and genetic testing specialist 23andMe is ...

As it is, we are alleged of intruding on Parliamentary and Executive functions.” Story continues below this ad The court allowed the listing of the application for hearing along with the petition on ...

fasting glucose and homeostasis model assessment of β-cell function) and glycosylated haemoglobin (HbA1c)). To assess the direct effect of genetically proxied lipid-lowering therapies on full-course ...

Accelerate your tech game Paid Content How the New Space Race Will Drive Innovation How the metaverse will change the future of work and society Managing the Multicloud The Future of the Internet ...

Correspondence to: MrC D Johnson University Surgical Unit, Mail Point 816, Southampton General Hospital, Southampton BH24 4EW, UK; c.d.johnsonsoton.ac.uk If you wish to reuse any or all of this ...

School of Health and Elderly Care, Shandong Women’s University, Jinan 250300, China ...